Auto-generated from public data. Not the firm's stated position.
EIR Ventures appears to focus on early-stage biotech and healthtech companies in the €0.1M to €1.5M check size range, with recent portfolio activity suggesting an emphasis on therapeutic development across functional biology, gastrointestinal, and oncology immunotherapy sectors.
Generated 13 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from EIR Ventures's website.
Molecular biologist with 20 years in venture investment, company building, and executive leadership in academic and pharma spin-outs.
Medical doctor with PhD in clinical epidemiology and experience in healthcare business development and management consulting.
Physician and scientist with successful exits in medical technology and experience as partner at HealthCap and The Column Group.
PhD in protein chemistry and immunology with 20 years in life science venture capital and creation of 30+ companies.
Physician with law degree and pharma industry experience in rare diseases, immunology, and oncology strategy.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.